Travis Murdoch is Chief Executive Officer at HI-Bio. Prior to HI-Bio, Travis was a life sciences investor with Softbank Vision Fund, where he oversaw investments in Relay Therapeutics (NASDAQ: RLAY), Vividion Therapeutics (Acq by: BAYRY), Seer (NASDAQ: SEER), VIR (NASDAQ: VIR), Zymergen (NASDAQ: ZY), ElevateBio, Encoded Therapeutics, Insitro, Karius and Collective Health. He was previously a Principal at Third Rock Ventures, and a consultant at McKinsey & Company. Travis is a gastroenterologist who worked with Northern communities in Canada.
He trained in gastroenterology with a focus on inflammatory bowel diseases (IBD) at the University of Calgary and internal medicine at the University of Toronto. Travis studied immunology at Oxford University as a Rhodes Scholar and medicine at the University of Alberta.